HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19

Divesting ScarAway Wound-Care Brand Required For US FTC Approval Of HRA Acquisition

Executive Summary

Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.

You may also be interested in...



If Successful, HRA Pharma Acquisition Will Complete Perrigo’s Pivot Towards Self-Care

If its acquisition of France's HRA Pharma completes, Perrigo will have “enough growth in our back pocket for the next three to five years without making any further acquisitions,” says the firm’s UK & Ireland chief, Neil Lister, in an exclusive interview with HBW Insight. 

Perrigo Feels Chill From Q3 Results Due To ‘Unfulfilled’ Demand On Supply Chain Disruptions

“Unfulfilled orders' from retailers and other product distributors due to supply chain disruptions slowed revenues, net income and earnings per share during the quarter and prompted lower full-year guidance while also leaving analysts with doubts.

Like COVID-19 Impact On Supply Chain, Expert Says Global Demand For Goods ‘Unprecedented’

UCLA professor Chris Tang says like most US businesses relying on supplies or production from outside the country, particularly from China, consumer health and beauty and personal care product companies should expect at least another year of supply disruption.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS152113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel